Why Insulet Stock Rocked the Market Today
Medical device maker 's (NASDAQ: PODD) stock was the cure for the investor blues on Wednesday. Following news of a large insider buy, the shares subsequently shot more than 6% higher on the day. That was well higher than the sub-0.4% increase of the S 500 index.
The inside buyer of Insulet stock was none other than its CEO, James Hollingshead. In a regulatory filing, the specialty healthcare company divulged that Hollingshead had purchased 5,550 shares of its common stock on Monday.
While that doesn't look at first blush to be a big-time purchase, Insulet stock currently has a triple-digit price tag. As a result, that buy-in cost the company's leader just over $1 million.
Source Fool.com
Insulet Corp. Stock
€164.05
2.850%
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Insulet Corp..
As a result the target price of 215 € shows a positive potential of 31.06% compared to the current price of 164.05 € for Insulet Corp..
